High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer

Eddie Reed, John Edward Janik, Michael A. Bookman, Mace Rothenberg, John Smith, Robert C. Young, Robert F. Ozols, Louis Vandermolen, Elise Kohn, Joan L. Jacob, Terri L. Cornelison

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: We investigated whether carboplatin myelosuppression could be favorably modulated by the administration of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with advanced-stage ovarian cancer. Patients and Methods: Thirty-four patients with advanced-stage recurrent ovarian cancer were treated with high-dose carboplatin (800 mg/m2 per 35-day cycle) and rGM-CSF. rGM-CSF was administered as a daily subcutaneous injection starting 72 hours after the carboplatin dose and continuing until 7 days beyond the WBC nadir. rGM-CSF was administered in a phase I fashion. Seven patients were treated at an rGM-CSF dose of 3 μg/kg, 11 at 5 μg/kg, 10 at 10 μg/kg, and six at 20 μg/kg. Results: rGM-CSF-related toxicities that were not dose-related included nonneutropenic fever, rib pain, acute hypersensitivity reaction, and pericarditis. At the rGM-CSF dose of 20 μg/kg, debilitating malaise was seen in four of six patients and this was the dose-limiting tox-icity. Patient tolerance of the 3-μg/kg and 5-μg/kg doses was good, but tolerance was limited for the 10-μg/kg dose. Febrile neutropenia was seen in four of seven patients at 3 μg/kg, two of 11 at 5 μg/kg, two of 10 at 10 μg/kg, and one of six at 20 μg/kg. Cumulative carboplatin myelotoxicity was blunted only in respect to WBC count, and not for platelets or RBCs. Gastrointestinal bleeding was seen in seven patients. The administered dose-intensity of carboplatin averaged 134 mg/m2/wk for the cohort, or 670 mg/m2 per 35-day cycle. There were two clinical complete responses and eleven partial responses, for a response rate of 38%. Conclusion: rGM-CSF appears to be effective and tolerable at 5 μg/kg/d administered subcutaneously, if given with carboplatin doses up to approximately 600 mg/m2 over 35 days. The use of rGM-CSF with high-dose carboplatin is associated with a substantial response rate in poor-prognosis ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)2118-2126
Number of pages9
JournalJournal of Clinical Oncology
Volume11
Issue number11
DOIs
StatePublished - Jan 1 1993

Fingerprint

Carboplatin
Granulocyte-Macrophage Colony-Stimulating Factor
Ovarian Neoplasms
Febrile Neutropenia
Pericarditis
Ribs
Subcutaneous Injections
Platelet Count
Hypersensitivity
Fever
Hemorrhage
Pain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reed, E., Janik, J. E., Bookman, M. A., Rothenberg, M., Smith, J., Young, R. C., ... Cornelison, T. L. (1993). High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. Journal of Clinical Oncology, 11(11), 2118-2126. https://doi.org/10.1200/JCO.1993.11.11.2118

High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. / Reed, Eddie; Janik, John Edward; Bookman, Michael A.; Rothenberg, Mace; Smith, John; Young, Robert C.; Ozols, Robert F.; Vandermolen, Louis; Kohn, Elise; Jacob, Joan L.; Cornelison, Terri L.

In: Journal of Clinical Oncology, Vol. 11, No. 11, 01.01.1993, p. 2118-2126.

Research output: Contribution to journalArticle

Reed, E, Janik, JE, Bookman, MA, Rothenberg, M, Smith, J, Young, RC, Ozols, RF, Vandermolen, L, Kohn, E, Jacob, JL & Cornelison, TL 1993, 'High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer', Journal of Clinical Oncology, vol. 11, no. 11, pp. 2118-2126. https://doi.org/10.1200/JCO.1993.11.11.2118
Reed, Eddie ; Janik, John Edward ; Bookman, Michael A. ; Rothenberg, Mace ; Smith, John ; Young, Robert C. ; Ozols, Robert F. ; Vandermolen, Louis ; Kohn, Elise ; Jacob, Joan L. ; Cornelison, Terri L. / High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 11. pp. 2118-2126.
@article{c0207854572e4c4bb3deed48467870ec,
title = "High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer",
abstract = "Purpose: We investigated whether carboplatin myelosuppression could be favorably modulated by the administration of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with advanced-stage ovarian cancer. Patients and Methods: Thirty-four patients with advanced-stage recurrent ovarian cancer were treated with high-dose carboplatin (800 mg/m2 per 35-day cycle) and rGM-CSF. rGM-CSF was administered as a daily subcutaneous injection starting 72 hours after the carboplatin dose and continuing until 7 days beyond the WBC nadir. rGM-CSF was administered in a phase I fashion. Seven patients were treated at an rGM-CSF dose of 3 μg/kg, 11 at 5 μg/kg, 10 at 10 μg/kg, and six at 20 μg/kg. Results: rGM-CSF-related toxicities that were not dose-related included nonneutropenic fever, rib pain, acute hypersensitivity reaction, and pericarditis. At the rGM-CSF dose of 20 μg/kg, debilitating malaise was seen in four of six patients and this was the dose-limiting tox-icity. Patient tolerance of the 3-μg/kg and 5-μg/kg doses was good, but tolerance was limited for the 10-μg/kg dose. Febrile neutropenia was seen in four of seven patients at 3 μg/kg, two of 11 at 5 μg/kg, two of 10 at 10 μg/kg, and one of six at 20 μg/kg. Cumulative carboplatin myelotoxicity was blunted only in respect to WBC count, and not for platelets or RBCs. Gastrointestinal bleeding was seen in seven patients. The administered dose-intensity of carboplatin averaged 134 mg/m2/wk for the cohort, or 670 mg/m2 per 35-day cycle. There were two clinical complete responses and eleven partial responses, for a response rate of 38{\%}. Conclusion: rGM-CSF appears to be effective and tolerable at 5 μg/kg/d administered subcutaneously, if given with carboplatin doses up to approximately 600 mg/m2 over 35 days. The use of rGM-CSF with high-dose carboplatin is associated with a substantial response rate in poor-prognosis ovarian cancer patients.",
author = "Eddie Reed and Janik, {John Edward} and Bookman, {Michael A.} and Mace Rothenberg and John Smith and Young, {Robert C.} and Ozols, {Robert F.} and Louis Vandermolen and Elise Kohn and Jacob, {Joan L.} and Cornelison, {Terri L.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.11.2118",
language = "English (US)",
volume = "11",
pages = "2118--2126",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer

AU - Reed, Eddie

AU - Janik, John Edward

AU - Bookman, Michael A.

AU - Rothenberg, Mace

AU - Smith, John

AU - Young, Robert C.

AU - Ozols, Robert F.

AU - Vandermolen, Louis

AU - Kohn, Elise

AU - Jacob, Joan L.

AU - Cornelison, Terri L.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: We investigated whether carboplatin myelosuppression could be favorably modulated by the administration of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with advanced-stage ovarian cancer. Patients and Methods: Thirty-four patients with advanced-stage recurrent ovarian cancer were treated with high-dose carboplatin (800 mg/m2 per 35-day cycle) and rGM-CSF. rGM-CSF was administered as a daily subcutaneous injection starting 72 hours after the carboplatin dose and continuing until 7 days beyond the WBC nadir. rGM-CSF was administered in a phase I fashion. Seven patients were treated at an rGM-CSF dose of 3 μg/kg, 11 at 5 μg/kg, 10 at 10 μg/kg, and six at 20 μg/kg. Results: rGM-CSF-related toxicities that were not dose-related included nonneutropenic fever, rib pain, acute hypersensitivity reaction, and pericarditis. At the rGM-CSF dose of 20 μg/kg, debilitating malaise was seen in four of six patients and this was the dose-limiting tox-icity. Patient tolerance of the 3-μg/kg and 5-μg/kg doses was good, but tolerance was limited for the 10-μg/kg dose. Febrile neutropenia was seen in four of seven patients at 3 μg/kg, two of 11 at 5 μg/kg, two of 10 at 10 μg/kg, and one of six at 20 μg/kg. Cumulative carboplatin myelotoxicity was blunted only in respect to WBC count, and not for platelets or RBCs. Gastrointestinal bleeding was seen in seven patients. The administered dose-intensity of carboplatin averaged 134 mg/m2/wk for the cohort, or 670 mg/m2 per 35-day cycle. There were two clinical complete responses and eleven partial responses, for a response rate of 38%. Conclusion: rGM-CSF appears to be effective and tolerable at 5 μg/kg/d administered subcutaneously, if given with carboplatin doses up to approximately 600 mg/m2 over 35 days. The use of rGM-CSF with high-dose carboplatin is associated with a substantial response rate in poor-prognosis ovarian cancer patients.

AB - Purpose: We investigated whether carboplatin myelosuppression could be favorably modulated by the administration of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with advanced-stage ovarian cancer. Patients and Methods: Thirty-four patients with advanced-stage recurrent ovarian cancer were treated with high-dose carboplatin (800 mg/m2 per 35-day cycle) and rGM-CSF. rGM-CSF was administered as a daily subcutaneous injection starting 72 hours after the carboplatin dose and continuing until 7 days beyond the WBC nadir. rGM-CSF was administered in a phase I fashion. Seven patients were treated at an rGM-CSF dose of 3 μg/kg, 11 at 5 μg/kg, 10 at 10 μg/kg, and six at 20 μg/kg. Results: rGM-CSF-related toxicities that were not dose-related included nonneutropenic fever, rib pain, acute hypersensitivity reaction, and pericarditis. At the rGM-CSF dose of 20 μg/kg, debilitating malaise was seen in four of six patients and this was the dose-limiting tox-icity. Patient tolerance of the 3-μg/kg and 5-μg/kg doses was good, but tolerance was limited for the 10-μg/kg dose. Febrile neutropenia was seen in four of seven patients at 3 μg/kg, two of 11 at 5 μg/kg, two of 10 at 10 μg/kg, and one of six at 20 μg/kg. Cumulative carboplatin myelotoxicity was blunted only in respect to WBC count, and not for platelets or RBCs. Gastrointestinal bleeding was seen in seven patients. The administered dose-intensity of carboplatin averaged 134 mg/m2/wk for the cohort, or 670 mg/m2 per 35-day cycle. There were two clinical complete responses and eleven partial responses, for a response rate of 38%. Conclusion: rGM-CSF appears to be effective and tolerable at 5 μg/kg/d administered subcutaneously, if given with carboplatin doses up to approximately 600 mg/m2 over 35 days. The use of rGM-CSF with high-dose carboplatin is associated with a substantial response rate in poor-prognosis ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0027428038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027428038&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.11.2118

DO - 10.1200/JCO.1993.11.11.2118

M3 - Article

C2 - 8229126

AN - SCOPUS:0027428038

VL - 11

SP - 2118

EP - 2126

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -